BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34121344)

  • 1. Effectiveness and Safety of High-Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance.
    Correll CK; Shrader P; Dennos A; Phillips T; Shiff NJ; Verstegen RHJ; Beukelman T;
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1770-1779. PubMed ID: 34121344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Mannion ML; Xie F; Horton DB; Ringold S; Correll CK; Dennos A; Beukelman T;
    J Rheumatol; 2021 Aug; 48(8):1322-1329. PubMed ID: 32934124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Ringold S; Dennos AC; Kimura Y; Beukelman T; Shrader P; Phillips TA; Kohlheim M; Schanberg LE; Yeung RSM; Horton DB;
    Arthritis Care Res (Hoboken); 2023 Apr; 75(4):715-723. PubMed ID: 35921198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.
    Ringold S; Hendrickson A; Abramson L; Beukelman T; Blier PR; Bohnsack J; Chalom EC; Gewanter HL; Gottlieb B; Hollister R; Hsu J; Hudgins A; Ilowite NT; Klein-Gitelman M; Lindsley C; Lopez Benitez JM; Lovell DJ; Mason T; Milojevic D; Moorthy LN; Nanda K; Onel K; Prahalad S; Rabinovich CE; Ray L; Rouster-Stevens K; Ruth N; Shishov M; Spalding S; Syed R; Stoll M; Vehe RK; Weiss JE; White AJ; Wallace CA; Sobel RE
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):529-37. PubMed ID: 25331530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
    Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
    Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry.
    Batthish M; Berard R; Cabral D; Bolaria R; Chédeville G; Duffy C; Gerhold K; Gerschman T; Huber A; Proulx-Gauthier JP; Rosenberg A; Rumsey D; Schmeling H; Shiff N; Soon G; Bruns A; Tucker L; Guzman J;
    Rheumatology (Oxford); 2020 Oct; 59(10):2796-2805. PubMed ID: 32044978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
    Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
    McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
    Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
    Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER.
    Bethencourt Baute JJ; Sanchez-Piedra C; Ruiz-Montesinos D; Medrano San Ildefonso M; Rodriguez-Lozano C; Perez-Pampin E; Ortiz A; Manrique S; Roselló R; Hernandez V; Campos C; Sellas A; Sifuentes-Giraldo WA; García-González J; Sanchez-Alonso F; Díaz-González F; Gómez-Reino JJ; Bustabad Reyes S;
    Arthritis Res Ther; 2018 Oct; 20(1):227. PubMed ID: 30305158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.
    Janow G; Schanberg LE; Setoguchi S; Hasselblad V; Mellins ED; Schneider R; Kimura Y;
    J Rheumatol; 2016 Sep; 43(9):1755-62. PubMed ID: 27307527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
    Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD;
    Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down Syndrome-Associated Arthritis Cohort in the New Childhood Arthritis and Rheumatology Research Alliance Registry: Clinical Characteristics, Treatment, and Outcomes.
    Jones JT; Smith C; Becker ML; Lovell D;
    Arthritis Care Res (Hoboken); 2021 Dec; 73(12):1739-1745. PubMed ID: 33242376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.